Solaris Resources Inc. (CVE:SLS – Get Free Report) shares fell 2.7% on Thursday . The company traded as low as C$5.95 and last traded at C$6.15. 53,313 shares were traded during mid-day trading, a decline of 60% from the average session volume of 132,199 shares. The stock had previously closed at C$6.32.
Solaris Resources Stock Down 2.7 %
The business’s 50 day moving average price is C$6.15 and its two-hundred day moving average price is C$6.15.
About Solaris Resources
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
See Also
- Five stocks we like better than Solaris Resources
- What Are Growth Stocks and Investing in Them
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Nebius Group: The Rising Star in AI Infrastructure
- The Risks of Owning Bonds
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
